Comparison of therapeutic effects of propofol or propofol combined with remifentanil in painless bronchoscopy examination

Comparison of therapeutic effects of cyclopol or propofol combined with remifentanil in painless bronchoscopy examination

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400081603

Enrollment

Unknown

Registered

2024-03-06

Start date

2024-03-06

Completion date

Unknown

Last updated

2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung disease

Interventions

Cyclopol combined with remifentanil group:Cyclopol

Propofol combined with remifentanil group:Propofol

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 64; 2. American Society of anesthesiologists (ASA) grade I ~ II;Mallampatis grade I ~ II; 3. Body mass index (BMI) ranged from 18 to 35.

Exclusion criteria

Exclusion criteria: 1.Patients with liver and kidney dysfunction, coagulation dysfunction or mental illness before operation; 2.Severe respiratory insufficiency; 3.History of severe allergy to the drug; 4.Refuse to participate in this trial.

Design outcomes

Primary

Measure	Time frame
Oxygen Saturation;blood pressure;heart rate;adverse reaction;	—

Secondary

Measure	Time frame
Comparison of general information;MOAA/S sedation score;Total amount of medication used;Patient and doctor satisfaction;	—

Countries

China

Contacts

Public ContactNie Jia

Zunyi Medical University Affiliated Hospital

963414483@qq.com+86 135 1852 3326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026